Related Experiment Video
Updated: Aug 19, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Response to third-line endocrine treatment for advanced breast cancer
T J Iveson1, J Ahern, I E Smith
1Breast Unit, Royal Marsden Hospital, London, U.K.
Abstract:
In a retrospective analysis we have identified 55 patients who have received three endocrine treatments for advanced breast cancer. 42% of these patients have benefitted from third-line endocrine treatment in terms of disease stabilisation, symptom relief or objective response and this was translated into statistically significant (P < 0.01) improved median survival of these patients (34 months) compared with those with progressive disease on third-line treatment (14 months). This suggests that third-line endocrine treatment might be of benefit to a number of patients with advanced breast cancer.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists